Rituximab for Anti-cytokine Autoantibody-Associated Diseases

Bio2RDF identifier

NCT01842386

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01842386

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01842386

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

30

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01842386 arm group 66ba162102bbf6ae31b522aec561735e [clinicaltrials_resource:NCT01842386/arm-group/66ba162102bbf6ae31b522aec561735e]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:4c3cb4f1b6774aae040152e2cdb4237b

brief summary [clinicaltrials_vocabulary:brief-summary]

Background: - ...... dose of rituximab.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The evaluation of adverse events to determine the safety and tolerability of rituximab in subjects with anticytokine autoantibody-associated diseases who are refractory to conventional treatment. At the conclusion of the study or if a serious adverse event occurs during the course of the study that may be related to the study drug. [clinicaltrials_resource:6faa0df0a2117449931043a8b0d36294]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The evaluation of adverse events to determine the safety and tolerability of rituximab in subjects with anticytokine autoantibody-associated diseases who are refractory to conventional treatment. At the conclusion of the study or if a serious adverse event occurs during the course of the study that may be related to the study drug. [clinicaltrials_resource:2180adbbd22bc596499ed73f995ddd6f]

The evaluation of adverse events to determine the safety and tolerability of rituximab in subjects with anticytokine autoantibody-associated diseases who are refractory to conventional treatment. At the conclusion of the study or if a serious adverse event occurs during the course of the study that may be related to the study drug. [clinicaltrials_resource:e6ceee13661de6cf297bbc0159520d12]

The evaluation of adverse events to determine the safety and tolerability of rituximab in subjects with anticytokine autoantibody-associated diseases who are refractory to conventional treatment. At the conclusion of the study or if a serious adverse event occurs during the course of the study that may be related to the study drug. [clinicaltrials_resource:eb393181fe5727c5cb0871d33ff7767c]

completion date [clinicaltrials_vocabulary:completion-date]

2018-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

Anticytokine autoantibo ...... fter completion of treatment.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01842386 [clinicaltrials_resource:cf2a2ab2b0a9da1556a80f51acce3328]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2013-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Rituximab/Rituxan [clinicaltrials_resource:8cfc3280c885c9ce8d7889052e3495c1]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Autoantibodies [clinicaltrials_resource:3c89ed8bdc1ee2b9f5b61de3fccb9378]

Rituximab [clinicaltrials_resource:fad6a221cf82b096e87404e0bdc662a4]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

No

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Anti-CD20

http://www.w3.org/2001/XMLSchema#string

Anticytokine Autoanitbody-Associated Disease

http://www.w3.org/2001/XMLSchema#string

Rituximab

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

National Institute of Allergy and Infectious Diseases (NIAID) [clinicaltrials_resource:d9a74aeb9c0d0448f38e08189395de72]

link [clinicaltrials_vocabulary:link]

NIH Clinical Center Detailed Web Page [clinicaltrials_resource:37e85611d4aa7000c07b7e4abae0c02d]

location [clinicaltrials_vocabulary:location]

National Institutes of Health Clinical Center, 9000 Rockville Pike [clinicaltrials_resource:52d85572c5d4aa0faa2049f3662b444e]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01842386

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

1

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Rituximab (Anti-CD20) for the ...... toantibody-Associated Diseases

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

130,082

http://www.w3.org/2001/XMLSchema#integer

overall contact [clinicaltrials_vocabulary:overall-contact]

Alexandra Freeman, M.D. [clinicaltrials_resource:26cde1db176793b0aaa59521fe1e7a2c]

overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]

Christa S Zerbe, M.D. [clinicaltrials_resource:7b5015a84698cc234d4287fe00eb6579]

overall official [clinicaltrials_vocabulary:overall-official]

Christa S Zerbe, M.D. [clinicaltrials_resource:ec0cabc7d1af97519c6e1e4a629bea54]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Federal Government [clinicaltrials_resource:15a952dd0198445f4ddd5909936bc0e7]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reference [clinicaltrials_vocabulary:reference]

14695413 [pubmed:14695413]

16177125 [pubmed:16177125]

21109174 [pubmed:21109174]

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

13-I-0082

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

National Institutes of Health Clinical Center (CC) [clinicaltrials_resource:007a75579f26d0622489b79170d20561]

start date [clinicaltrials_vocabulary:start-date]

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01842386 study design [clinicaltrials_resource:c06712f7698afba321a75afa18c5fb52]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01842386

verification date [clinicaltrials_vocabulary:verification-date]

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01842386

http://www.w3.org/2001/XMLSchema#string